Caballero-Bermejo, Antonio FDarnaude-Ximénez, IgnacioAguilar-Pérez, MyriamGomez-Lopez, AliciaSancho-López, AránzazuLópez García-Gallo, CristinaDíaz Nuevo, GemaDiago-Sempere, ElenaRuiz-Antorán, BelénAvendaño-Solá, CristinaUssetti-Gil, PiedadPBISA01-Study Group2023-11-142023-11-142023-10-18Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0061323.http://hdl.handle.net/20.500.12105/16667Isavuconazole's (ISA) pharmacokinetics was studied among lung transplant recipients to evaluate its bronchopulmonary penetration. This study included 13 patients and showed mean serum concentrations of 3.30 (standard deviation [SD] 0.45), 5.12 (SD 1.36), and 6.31 (SD 0.95) at 2 h, 4 h, and 24 h respectively. Mean concentrations in the epithelial lining fluid were 0.969 (SD 0.895), 2.141 (SD 1.265), and 2.812 (SD 0.693) at the same time points. ISA is a drug with a tolerable safety profile that achieves adequate concentrations in the lung.engVoRhttp://creativecommons.org/licenses/by/4.0/IsavuconazoleInvasive fungal infectionBronchoalveolar lavageTissue penetrationLung transplantTransplant RecipientsLungHumansBronchoalveolar Lavage FluidTriazolesAtribución 4.0 Internacional377875286710e006132310.1128/aac.00613-231098-6596Antimicrobial agents and chemotherapyopen access